Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 1.00 |
| ▸ | HMGCR | P04035 | 11/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.83 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.83 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.83 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.64 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | USP2 | O75604 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenivastatin SCHEMBL28594403 | 1.00 | SLCO1B1 (1.00) | SLCO1B1HMGCRHDAC1HDAC2HDAC6 | |
| Tenivastatin SCHEMBL28594405 | 1.00 | SLCO1B1 (1.00) | SLCO1B1HMGCRHDAC1HDAC2HDAC6 | |
| Tenivastatin SCHEMBL14137685 | 1.00 | SLCO1B1 (1.00) | SLCO1B1HMGCRHDAC1HDAC2HDAC6 | |
| Tenivastatin SCHEMBL14420544 | 1.00 | SLCO1B1 (1.00) | SLCO1B1HMGCRHDAC1HDAC2HDAC6 | |
| Tenivastatin SCHEMBL13934502 | 1.00 | SLCO1B1 (1.00) | SLCO1B1HMGCRHDAC1HDAC2HDAC6 | |
| Tenivastatin SCHEMBL25366987 | 1.00 | SLCO1B1 (1.00) | SLCO1B1HMGCRHDAC1HDAC2HDAC6 | |
| Tenivastatin SCHEMBL110804 | 1.00 | SLCO1B1 (1.00) | SLCO1B1HMGCRHDAC1HDAC2HDAC6 | |
| Tenivastatin SCHEMBL8239454 | 1.00 | SLCO1B1 (1.00) | SLCO1B1HMGCRHDAC1HDAC2HDAC6 | |
| Tenivastatin SCHEMBL28618339 | 0.99 | SLCO1B1 (0.98) | SLCO1B1HMGCRHDAC1HDAC2HDAC6 | |
| Tenivastatin SCHEMBL2987588 | 0.99 | SLCO1B1 (0.98) | SLCO1B1HMGCRHDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0276807-A2 | Lipid regulating compositions | WARNER-LAMBERT COMPANY (US) | 1988-08-03 | — | — | EP | claimed |
| WO-1988005296-A2 | LPID REGULATING COMPOSITIONS | WARNER-LAMBERT COMPANY (US) | 1988-07-28 | — | — | WO | claimed |
| US-20200030288-A1 | STATIN FOR PREVENTION/REDUCTION OF ISCHEMIA-RELATED DAMAGE | FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU (ES) | 2020-01-30 | — | — | US | disclosed |
| WO-2015181216-A1 | PREVENTION AND/OR TREATMENT OF ISCHEMIA/REPERFUSION INJURY | CONSORCI INSTITUT CATALÀ DE CIÈNCIES CARDIOVASCULARS (ES) | 2015-12-03 | — | — | WO | disclosed |
| EP-2949324-A1 | Prevention and/or treatment of ischemia/reperfusion injury | Consorci Institut Catala de Ciencies Cardiovasculars (ES) | 2015-12-02 | — | — | EP | disclosed |
| US-8779167-B2 | Method for preparing a statin compound by lactonization | PEKING UNIVERSITY FOUNDER GROUP CO., LTD. (CN) | 2014-07-15 | — | — | US | disclosed |
| US-8779167-B2 | Method for preparing a statin compound by lactonization | PEKING UNIVERSITY FOUNDER GROUP CO., LTD. (CN) | 2014-07-15 | — | — | US | disclosed |
| CN-103864611-A | Preparation method of simvastatin hydroxy acidified matter, composition, and preparation method and application of composition | SHENZHEN CHINA RESOURCES GOSUN PHARMACEUTICAL CO LTD | 2014-06-18 | — | — | CN | disclosed |
| US-20130102635-A1 | Methods for Treating Disorders Associated with Hyperlipidemia in a Mammal | AEGERION PHARMACEUTICALS, INC. | 2013-04-25 | — | — | US | disclosed |
| US-20120296099-A1 | METHODS FOR PREPARING STATIN COMPOUNDS BY LACTONIZATION | PKU INTERNATIONAL HEALTHCARE GROUP CO., LTD. (CN) | 2012-11-22 | — | — | US | disclosed |
| US-20120296099-A1 | METHODS FOR PREPARING STATIN COMPOUNDS BY LACTONIZATION | PKU INTERNATIONAL HEALTHCARE GROUP CO., LTD. (CN) | 2012-11-22 | — | — | US | disclosed |
| US-20070155676-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155675-A1 | Substituted azetidinone compunds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155675-A1 | Substituted azetidinone compunds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
| US-7235543-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235543-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| WO-2007047880-A2 | COMPOSITIONS FOR LOWERING SERUM CHOLESTEROL AND/OR TRIGLYCERIDES | AEGERION PHARMACEUTICALS (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070093527-A1 | Methods for treating disorders associated with hyperlipidemia in a mammal | AEGERION PHARMACEUTICALS, INC. | 2007-04-26 | — | — | US | disclosed |
| US-7208486-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208486-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120296099-A1 | METHODS FOR PREPARING STATIN COMPOUNDS BY LACTONIZATION | HMGCR, LPO, ACSL4 | SLCO1B1 149/4885HMGCR 1/4885HDAC1 673/4885 |
| US-20130102635-A1 | Methods for Treating Disorders Associated with Hyperlipidemia in a Mammal | HMGCR, MTTP, CETP | SLCO1B1 563/4885HMGCR 1/4885HDAC1 2015/4885 |
| US-20200030288-A1 | STATIN FOR PREVENTION/REDUCTION OF ISCHEMIA-RELATED DAMAGE | TNNI3, HMGCR, FABP3 | SLCO1B1 624/4885HMGCR 2/4885HDAC1 1161/4885 |
| US-20070155675-A1 | Substituted azetidinone compunds, processes for preparing the same, formulations and uses thereof | APOB, NPC1L1, CYP46A1 | SLCO1B1 2333/4885HMGCR 78/4885HDAC1 2983/4885 |
| US-20070155676-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | APOB, NPC1L1, CYP46A1 | SLCO1B1 3052/4885HMGCR 29/4885HDAC1 4208/4885 |
| US-20070093527-A1 | Methods for treating disorders associated with hyperlipidemia in a mammal | HMGCR, MTTP, CETP | SLCO1B1 563/4885HMGCR 1/4885HDAC1 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.